Nuvectis Pharma Inc. (NVCT)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know
The mean of analysts' price targets for Nuvectis Pharma (NVCT) points to a 56.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?
The consensus price target hints at a 61.5% upside potential for Nuvectis Pharma (NVCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now?
Does Nuvectis Pharma, Inc. (NVCT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Nuvectis Pharma Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 1 | $8 | $18.83 | $10.83 | 135.37% |
 Joseph Castro Nuveen LLC | 40,823 | $412,558.56 | $770,534.12 | $357,975.56 | 86.77% |
 Hui Fai Tam Caitong International Asset Management Co. Ltd. | 15 | $179.1 | $301.5 | $122.4 | 68.34% |
 Christopher C. Powers Farther Finance Advisors, LLC | 21 | $250.74 | $451.92 | $201.18 | 80.23% |
 Derek Ripp Austin Wealth Management, LLC | 20,125 | $196,621.25 | $433,090 | $236,468.75 | 120.27% |
Nuvectis Pharma Inc. (NVCT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Nuvectis Pharma Inc. ever had a stock split?
Nuvectis Pharma Inc. Profile
| Biotechnology Industry | Healthcare Sector | Ron Bentsur CEO | NASDAQ (CM) Exchange | 67080T108 CUSIP |
| US Country | 16 Employees | - Last Dividend | - Last Split | 4 Feb 2022 IPO Date |
Overview
Nuvectis Pharma, Inc. is a dynamic biopharmaceutical company dedicated to the creation of precision medicines aimed at addressing critical unsolved medical challenges within the field of oncology. The firm's focus is on the discovery and development of novel therapeutic agents that provide targeted solutions for cancer patients facing dire prognoses due to the lack of effective treatments. Established in 2020 and headquartered in Fort Lee, New Jersey, Nuvectis Pharma has carved out a niche in oncology medicine through its commitment to innovation and patient-centered care. Originally known as Centry Pharma, Inc., the company underwent a rebranding to Nuvectis Pharma, Inc. in July 2021, marking a new chapter in its mission to bring groundbreaking cancer treatments to the market.
Products and Services
- NXP800
Nuvectis Pharma's leading product candidate, NXP800, stands out as a pioneering small molecule therapy currently in Phase 1b clinical trials. This drug is designed specifically for patients suffering from platinum-resistant, ARID1a-mutated ovarian carcinoma. By focusing on a subset of ovarian cancer characterized by specific genetic mutations, NXP800 exemplifies the company’s strategy of targeting precise cancer pathways, potentially offering a new hope for patients with limited treatment options.
- NXP900
The company is also at the forefront of developing NXP900, another innovative small molecule drug candidate. Currently undergoing Phase 1a clinical trials, NXP900 is engineered to inhibit the activity of the Proto-oncogene c-Src and YES1 kinases. The dual focus on these particular kinases underscores Nuvectis Pharma’s dedication to exploiting unique targets within the cancer cell signaling network, paving the way for treatments that can overcome the complexities of cancer resistance and progression.
In its quest to bring these promising therapies to market, Nuvectis Pharma has secured strategic license agreements with reputable institutions. These include a partnership with the CRT Pioneer Fund for NXP800 and any related derivatives, and a collaboration with the University of Edinburgh for NXP900 and its associated derivatives. These partnerships not only bolster the company's portfolio but also enhance its capability to navigate the challenging landscape of drug development in oncology.
